Macrophage Pharma is an immuno-oncology R&D company based in Windsor, England, focused on macrophage modulation in the tumour microenvironment. The company is advancing its ESM™ technology platform to deliver small-molecule drugs selectively to macrophages. Its lead program is a macrophage-targeting p38 MAPK inhibitor with clinical trials scheduled to start in 2018. The financing will enable completion of the first clinical study of that lead candidate and the advancement of two additional discovery candidates into preclinical development. Macrophage Pharma also plans to add a fourth macrophage-targeted project to its pipeline. Macrophage Pharma, based in Windsor, UK, focuses on discovery and development of therapies designed to enhance anti-tumour immune responses by targeting tumour-associated macrophages. The company acquired global rights to the Esterase Sensitive Motif (ESM) platform from Chroma Therapeutics, a technology that delivers small-molecule drugs selectively to tumour-associated macrophages. Its lead program is a novel macrophage-targeting p38 MAPK inhibitor with clinical trials scheduled to start in 2018, and the company also has additional discovery-stage proprietary programmes. Macrophage plans to use the funds to complete preclinical development of its lead p38 MAPK inhibitor and to advance two additional discovery candidates into preclinical development. The ESM platform is described as enabling next-generation immunotherapies across multiple cancers by activating the body’s natural immune system to fight tumours. The company is led by interim chair Ian Miscampbell and is advancing both its drug candidates and the newly acquired platform toward clinical development.

Total raised

$11M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2017